Insights

Gathering insights about Ntara…

Similar companies to Ntara

Ntara Tech Stack

Ntara uses 8 technology products and services including Google AdWords, Microsoft Clarity, SoapUI, and more. Explore Ntara's tech stack below.

Google AdWords
Advertising
Microsoft Clarity
Analytics
SoapUI
Data Management Platforms
Salsify
Digital Asset Management
.NET
Programming Languages
three.js
Programming Languages
Yoast SEO
Search Engines
ZURB Foundation
UI Frameworks

Media & News

Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development
VANCOUVER, British Columbia, July 10, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to highlight the strength and scientific leadership of its established Scientific Advisory Board (SAB). Rakovina's SAB is composed of internationally recognized experts in oncology, AI-driven drug development, and precision medicine. The board plays a vital role in shaping the company's research strategy, pipeline advancement, and translational development initiatives.
Jul 10, 2025 | www.globenewswire.com
Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024
SAN DIEGO , Oct. 16, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced a correction to the press release previously issued by Kintara on October 16, 2024. Kintara announced today that its Board of Directors (the "Board") has approved a reverse stock split of Kintara's common stock at a ratio of 1-for-35.
Oct 16, 2024 | www.prnewswire.com
Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences
SAN DIEGO , Oct. 16, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its Board of Directors (the "Board") has approved a reverse stock split of Kintara's common stock at a ratio of 1-for-35. Kintara's common stock is expected to begin trading on a post-reverse stock split basis on the Nasdaq Capital Market on October 17, 2024, under the new name TuHURA Biosciences, Inc. and under the new symbol "HURA" following the anticipated closing of the merger (the "Merger") with TuHURA Biosciences, Inc. ("TuHURA"), with a new CUSIP number 898920 103.
Oct 16, 2024 | www.prnewswire.com
Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024
SAN DIEGO , Oct. 15, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced a correction to the press release previously issued by Kintara on October 14, 2024, regarding a record date for the issuance of the Contingent Value Rights ("CVRs") to stockholders of Kintara pursuant to the definitive merger agreement (the "Merger Agreement") with TuHURA Biosciences, Inc. ("TuHURA"). Kintara announced today that the CVRs will not be issued to stockholders of record of Kintara based on a record date of October 17, 2024, but rather will be issued stockholders of record of Kintara immediately prior to the planned reverse stock split that will be consummated immediately prior to the proposed Merger.
Oct 15, 2024 | www.prnewswire.com
Kintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024
SAN DIEGO , Oct. 14, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced a record date of October 17, 2024 (the "Record Date") for the issuance of Contingent Value Rights ("CVRs") to stockholders of record of Kintara as of the Record Date. As previously disclosed, in April 2024 Kintara entered into a definitive merger agreement (the "Merger Agreement") with TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kayak Mergeco, Inc., Kintara's wholly-owned subsidiary, whereby Kayak Mergeco will merge with and into TuHURA, with TuHURA surviving the merger and becoming Kintara's direct, wholly-owned subsidiary (the "Merger").
Oct 14, 2024 | www.prnewswire.com
Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update
SAN DIEGO , Oct. 8, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal fourth quarter ended June 30, 2024, and provided a corporate update. Recent Corporate Developments As previously disclosed, in April 2024 Kintara entered into a definitive merger agreement (the "Merger Agreement") with TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kayak Mergeco, Inc., Kintara's wholly-owned subsidiary, whereby Kayak Mergeco will merge with and into TuHURA with TuHURA surviving the merger and becoming Kintara's direct, wholly-owned subsidiary (the "Merger").
Oct 08, 2024 | www.prnewswire.com
Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024
SAN DIEGO , Sept. 20, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced it adjourned the Special Meeting of Stockholders (the "Special Meeting") held on September 20, 2024.
Sep 20, 2024 | www.prnewswire.com

Ntara's Email Address Formats

Ntara uses at least 1 format(s):

Ntara Email Formats	Example	Percentage
Last@ntara.com	Doe@ntara.com	86%
First.Last@ntara.com	John.Doe@ntara.com	8%
FirstLast@ntara.com	JohnDoe@ntara.com	4%
First@ntara.com	John@ntara.com	2%

Frequently Asked Questions

Where is Ntara's headquarters located?

Ntara's main headquarters is located at 105 East Walnut Street, Suite 20. The company has employees across 3 continents, including North AmericaAfricaAsia.

What is Ntara's phone number?

You can contact Ntara's main corporate office by phone at

+1-423-926-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Ntara's stock symbol?

Ntara is a publicly traded company; the company's stock symbol is KTRA.

What is Ntara's official website and social media links?

Ntara's official website is ntara.com and has social profiles on LinkedIn.

How much revenue does Ntara generate?

As of December 2025, Ntara's annual revenue is estimated to be $6M.

What is Ntara's SIC code NAICS code?

Ntara's SIC code is 6512 - Operators of Nonresidential Buildings NAICS code is 5415 - Computer Systems Design and Related Services.

How many employees does Ntara have currently?

As of December 2025, Ntara has approximately 70 employees across 3 continents, including North AmericaAfricaAsia. Key team members include Chief Executive Officer: A. D.Ceo: R. O.Coo | President Ntaragt: S. M.. Explore Ntara's employee directory with LeadIQ.

What industry does Ntara belong to?

Ntara operates in the IT Services and IT Consulting industry.

What technology does Ntara use?

Ntara's tech stack includes Google AdWordsMicrosoft ClaritySoapUISalsify.NETthree.jsYoast SEOZURB Foundation.

What is Ntara's email format?

Ntara's email format typically follows the pattern of Last@ntara.com. Find more Ntara email formats with LeadIQ.

When was Ntara founded?

Ntara was founded in 1999.

Ntara

Q: What is Ntara's official website and social media links?

Ntara's official website is ntara.com. Ntara has social profiles on LinkedIn.

Q: How many employees does Ntara have currently?

Ntara has approximately 70 employees.

Q: What technology does Ntara use?

Ntara's tech stack includes TeamCity, Nginx, CodePen, Censhare, YouTube.

IT Services and IT ConsultingTennessee, United States51-200 Employees

Ntara specializes in PIM, DAM, ecommerce consulting, & customer segmentation research. We consult with manufacturers & brands on large-scale digital transformation. We guide our clients through product data & asset process optimization. We implement and customize several PIM, DAM, and ecommerce platforms. And we conduct in-depth customer research and performance analysis to help our clients make data-driven decisions about strategy. 

Read our blog: https://www.ntara.com/blog

See how we help our clients: https://www.ntara.com/digital-case-studies

Company Overview

Headquarters: 105 East Walnut Street, Suite 20
Phone number: +1-423-926-****
Website: ntara.com
SIC Code: 6512 - Operators of Nonresidential Buildings
Stock Symbol: KTRA
NAICS Code: 5415 - Computer Systems Design and Related Services
Founded: 1999
Employees: 51-200

Media & News

Funding & Financials

$50M$100M
Ntara's revenue is estimated to be in the range of $50M$100M

Funding & Financials

$50M$100M
Ntara's revenue is estimated to be in the range of $50M$100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Ntara

Genuine

EYEMAGINE

Le Site

Velir

Elevated Third

Zivtech

Americaneagle.com

Devbridge Group

Constructive

Phase2

Ntara Tech Stack

Media & News

Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development

Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024

Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences

Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

Kintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update

Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024

Ntara's Email Address Formats

Frequently Asked Questions

Where is Ntara's headquarters located?

What is Ntara's phone number?

What is Ntara's stock symbol?

What is Ntara's official website and social media links?

How much revenue does Ntara generate?

What is Ntara's SIC code NAICS code?

How many employees does Ntara have currently?

What industry does Ntara belong to?

What technology does Ntara use?

What is Ntara's email format?

When was Ntara founded?

Ntara

Company Overview

Media & News

Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development

Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024

Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?